Mesoblast's (ASX:MSB) cell therapy showed improved outcomes in heart disease patients based on data from a phase 3 trial, according to a Tuesday filing with the Australian bourse.
The randomized controlled study, named DREAM-HF, showed that a single intramyocardial injection of Revascor-branded allogeneic cell therapy, rexlemestrocel-L, showed an improvement in the survival of high-risk patients with ischemic heart failure and inflammation, the filing said.
Results from the trial were published in November in the peer-reviewed European Journal of Heart Failure, the filing added.
The company's shares were up almost 2% in recent Tuesday trade.
Price (AUD): $1.83, Change: $+0.03, Percent Change: +1.50%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。